Ruiyi Biotechnology

Ruiyi Biotechnology is a China-based healthcare company focused on cancer early detection, gut microbiome health, and related diagnostic and service platforms. Founded in 2014 in Shanghai, the company develops and commercializes non-invasive in vitro diagnostic products, including stool DNA methylation testing for colorectal cancer and urine-based methylation testing for bladder cancer. The company also offers microbiome-related health solutions, pathogen detection, scientific research services, laboratory automation, and a CDMO platform for medical devices and IVD products. Ruiyi appears to operate as a commercial-stage diagnostics and health technology company rather than a therapeutics developer, with emphasis on precision screening, digitalized workflows, and regional laboratory/manufacturing infrastructure in China.